Neurofibromatosis Type 2Phase 2ASSISTNCT07707947
Selumetinib for NF2-Related Schwannomatosis
A Phase 2 study testing Selumetinib in people with Neurofibromatosis Type 2 and NF2, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors. Read more about this study
- Who is it for?
- Ages 3 years and older
- Conditions the study is for
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis
- What is being tested?
- Selumetinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2026to 31 Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients must have a pathogenic variant in the NF2 gene (either in the germline or in two NF2-related tumors)OR a confirmed diagnosis of NF2 by fulfilling National Institute of Health (NIH)criteria or Manchester criteria:
- The genetic test report should be issued by companies or hospitals with corresponding qualifications.
- The NIH criteria includes presence of:
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity.
- The Manchester criteria includes presence of:
Show all 56Show fewer
- Bilateral vestibular schwannomas, OR
- First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR
- Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity,OR
- Multiple meningiomas (two or more)AND unilateral vestibular schwannoma OR
- any two of: schwannoma, glioma, neurofibroma, cataract.
- Subjects must have ≥1 measurable target vestibular schwannoma meeting all of the following conditions:
- Measurable on MRI with a minimum diameter ≥3 mm;
- Evidence of radiographic progression within the past 36 months according to REiNS criteria, OR documented clinical progression attributable to the target tumor (e.g., hearing decline, cranial nerve dysfunction).
- Subjects whose Word Recognition Score (WRS)ranging from 50%to 88%at the side of target vestibular schwannoma.
- The target tumor must be considered not amenable to surgery due to:
- High surgical risk (e.g., risk of neurological deficit), OR
- Patient refusal of surgery after adequate medical counseling.
- Male or female subjects aged ≥3 years at the time of informed consent.
- Adequate functional status
- Subjects aged ≥16 years:
- Karnofsky Performance Status ≥70,OR
- ECOG Performance Status 0-1
- Subjects aged <16 years:
- Lansky Performance Status ≥70
- Adequate organ and bone marrow function
- Laboratory values obtained within 28 days prior to enrollment must meet the following:
- Hematologic function
- Hemoglobin ≥9.0 g/dL
- Absolute neutrophil count (ANC)≥1.5 ×10⁹/L
- Platelet count ≥100 ×10⁹/L
- Hepatic function
- AST and ALT ≤2.5 ×ULN (≤2.0 ×ULN for pediatric subjects)
- Total bilirubin ≤ 1.5 ×ULN (≤3 ×ULN in subjects with documented Gilbert's syndrome)
- Renal function
- Serum creatinine ≤1.5 ×ULN, OR
- Creatinine clearance ≥60 mL/min/1 .73 m²(age-and BSA-adjusted)
- Cardiac function
- Left ventricular ejection fraction (LVEF)≥50%by echocardiography
- No clinically significant uncontrolled cardiac disease
- Pulmonary function • Peripheral oxygen saturation ≥92%on room air
- Reproductive and contraception requirements
- Females of childbearing potential
- Negative serum or urine pregnancy test prior to enrollment
- Must be postmenopausal ≥12 months, surgically sterile, or using a highly effective method of contraception throughout the study and for 3 months after the last dose
- Acceptable methods include:
- Hormonal contraception
- Intrauterine device (IUD)
- Long-acting reversible contraception
- Tubal ligation
- Oral contraception alone must be combined with a barrier method
- Males • Must be surgically sterile or agree to use barrier contraception with permicide during treatment and for 3 months after the last dose.
- Subjects must be able to swallow selumetinib capsules intact.
- Written informed consent must be obtained:
- From the subject if capable of providing consent;
- From a legally acceptable representative for minors or subjects lacking full decision-making capacity.
Who cannot join
- Concurrent involvement in study conduct:the subject is an employee of the Sponsor, Investigator, or study site who is directly involved in the planning, conduct, or management of this clinical study.
- Participation in another interventional clinical trial with an investigational medicinal product, or receipt of an investigational agent within 28 days (or 5 half-lives if known and longer)prior to first dose.
- Prior anti-cancer systemic therapies or prior radiotherapy that, in the investigator's judgment, would confound safety or efficacy assessment, unless completed ≥28 days prior to first dose (longer washout required for agents with prolonged biologic effect as specified in protocol appendix). Subjects who received prior local therapy (surgery or localized radiotherapy)are eligible if recovery is complete and target lesion remains measurable.
- Evidence or high suspicion of malignant peripheral nerve sheath tumor (MPNST)or other active malignancy requiring systemic therapy (past malignancy is allowed only if disease-free for ≥2 years, except for adequately treated basal cell carcinoma or in situ carcinoma).
- Significant cardiac disease or ECG abnormalities:
- Resting QTcF >470 ms (adults)[>450 ms for pediatric thresholds as specified in protocol appendix], or clinically significant baseline prolongation per investigator/medical monitor.
Show all 24Show fewer
- Clinically significant arrhythmia (symptomatic ventricular tachycardia, sustained ventricular tachycardia, uncontrolled atrial fibrillation). Subjects with well controlled atrial fibrillation may be considered after Medical Monitor review.
- Acute coronary syndrome within 6 months, unstable angina, symptomatic congestive heart failure NYHA class II-IV, or LVEF below institutional lower limit of normal (LLN)or <50%.
- Uncontrolled hypertension:systolic ≥140 mmHg or diastolic ≥90 mmHg despite optimal therapy (adult criteria);for pediatric subjects use age/height/gender percentiles per protocol appendix.
- Severe hepatic or renal impairment -e.g.,AST/ALT >5 ×ULN (or per protocol specified threshold for severe impairment), total bilirubin >3 ×ULN (unless Gilbert's syndrome).(See inclusion for minimum acceptable labs;exclude those with more severe dysfunction.)
- Ophthalmologic conditions:current or prior history of MEK-associated retinopathy / central serous retinopathy /retinal pigment epithelial detachment /retinal vein occlusion, or any active ocular condition judged by the investigator/ophthalmologist to increase the risk of serious ocular adverse events (e.g., uncontrolled glaucoma with elevated IOP and meaningful vision at risk). Subjects with stable, chronic ophthalmic findings that are not expected to worsen with MEK inhibition may be eligible after ophthalmology clearance.
- Known hypersensitivity to selumetinib or any excipients.
- Active, uncontrolled infection including:
- Positive HIV test (known HIV infection with uncontrolled disease or on unstable antiretroviral therapy that interacts with study drug)-no evidence AIDS and no contraindicating ART may be considered after Medical Monitor review.
- Active hepatitis B or C infection (HBsAg positive or HCV RNA positive). Subjects with resolved HBV (HBsAg negative, anti-HBc positive)may be eligible per local hepatology guidance and prophylaxis plan.
- Concomitant medications that:
- Are known to prolong QT interval and cannot be safely discontinued;OR
- Are strong CYP3A4 or CYP2C19 inducers/inhibitors that cannot be stopped and would significantly alter selumetinib exposure (refer to protocol drug-interaction appendix for permitted/forbidden lists).
- Gastrointestinal conditions that preclude reliable oral absorption (e.g., severe malabsorption, short bowel syndrome, recent (within 6 months)major intestinal resection)or inability to swallow intact capsules.
- Conditions requiring urgent neurosurgical intervention (e.g., symptomatic hydrocephalus requiring immediate shunting, life-threatening brainstem compression)-subjects requiring emergent neurosurgery are not eligible until stabilized and reevaluated.
- Prior organ transplantation (allogeneic)or ongoing immunosuppression that would confound safety assessment.
- Concomitant vitamin E†or other agents judged to have potential interaction with the study drug if they cannot be discontinued per protocol (e.g., vitamin E to be stopped ≥7 days before first dose if required by protocol).
- Pregnancy or breastfeeding at screening (positive pregnancy test). Female subjects of childbearing potential who are unwilling/unable to use acceptable contraception during the study and for the duration specified in the contraceptive guidance (see protocol)are excluded.
- Any other clinically significant medical, psychiatric, or social condition that, in the opinion of the investigator or Medical Monitor, would compromise subject safety or protocol compliance (including inability to undergo MRI, when MRI is required for tumor assessment).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070
Pinan Liu, PhD, 010-59976611, pinanliu@ccmu.edu.cn
About this study
Official title: A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1/2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.
Read the detailed description
NF2-related schwannomatosis (NF2-SWN) is a rare, autosomal dominant tumor predisposition syndrome characterized by bilateral vestibular schwannomas and multifocal schwannomas arising from cranial, spinal, and peripheral nerves, frequently leading to progressive hearing loss, neurological deficits, and substantial morbidity. This study will serve as a Substudy component of the "Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)" initiative, conducting a single-center, single-arm Phase II clinical trial aimed at evaluating the efficacy and safety of selumetinib in treating NF2-SWN-associated tumors. The study will enroll 20 patients diagnosed with NF2-related schwannomatosis (NF2-SWN) who have at least one measurable and progressive vestibular schwannoma and are aged ≥3 years. The primary endpoints include: ① Imaging response rate for NF2-SWN-associated vestibular schwannomas, assessed by a reduction of ≥20% in volume according to the REiNs criteria; ② Hearing response rate, defined as an improvement in speech recognition rate exceeding the 95% threshold difference. Secondary endpoints involve quality-of-life assessment: all patients will undergo evaluation using the NF2-SWN-specific Quality of Life Scale (NFTI-QOL), with additional pain scoring using the Numerical Rating Scale-11 (NRS-11) for patients with NF2-SWN-related intraspinal space-occupying lesions. The exploratory endpoints included: ① Imaging response rates for other NF2-SWN-related tumors excluding NF2-SWN-associated vestibular schwannomas: for meningiomas (non-vestibular schwannomas), objective imaging response defined as a volume reduction ≥20% per the REiNs criteria; for ependymomas, objective imaging response defined as a maximum diameter reduction ≥30% per the RECIST 1.1 criteria; total tumor burden; and the TSPO-PET/MRI-defined immune phenotype (immune-enriched vs. immune-depleted) and its association with treatment response in NF2-SWN-associated vestibular schwannomas. This study will provide further clinical evidence for targeted therapy of NF2-SWN.
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma, Ependymoma, Vestibular Schwannoma
- Being tested
- Selumetinib
- Keywords
- NF2-SWN, Selumetinib
- Medical subject headings
- Neurofibromatosis 2, Meningioma, Ependymoma, Neuroma, Acoustic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SelumetinibDrug
Also called KOSELUGO
Selumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment.
| Study group | Role | What they receive |
|---|---|---|
| Selumetinib | Experimental | Selumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment. Receives: Drug: Selumetinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate (ORR)in NF2-related vestibular schwannoma assessed according to the REiNS criteria
Partial response is defined as the sum volume of VS decrease ≥20% compared to baseline, confirmed by a consecutive scan after 1 to 3 treatment cycles after the first response. Complete response is defined as disappearance of VS, confirmed by a consecutive scan after 1 to 3 treatment cycles after the first response;
Measured: 12 months
Hearing Response Rate Based on Word Recognition Score (WRS) in Target Vestibular Schwannoma
Percentage of participants with WRS improvement exceeding the 95% critical difference from baseline in the ear associated with the target vestibular schwannoma.
Measured: 12 months
Pure Tone Average (PTA) Response Rate in Target Vestibular Schwannoma
Percentage of participants with a PTA decrease of at least 10 dB from baseline in the ear associated with the target vestibular schwannoma.
Measured: 12 months
Secondary outcomes (1)
Assess safety and tolerability especially for selumetinib
Incidence and severity of treatment -adverse events of ocular toxicity and cardiac toxicity graded according to CTCAE v6.0
Measured: From the first dose of study drug (Day 0) through 30 ± 3 days after the last dose administration.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start1 Dec 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurofibromatosis Type 2Studies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Selumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07707947
- Sponsor's protocol ID
- CS-2025-07
- Acronym
- ASSIST
- Status last verified
- Oct 2026
- First submitted
- 3 Jul 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared. This decision is based on: (1) the rare disease nature of NF2-SWN and small sample size (n=20), which increases re-identification risk even after de-identification; (2) protection of participant privacy and confidentiality as required by Chinese ethics regulations and the informed consent process; and (3) proprietary considerations of the study sponsor regarding investigational product data.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1/2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis
- ClinicalTrials.gov ID
- NCT07707947
- Acronym / sponsor ID
- ASSIST / CS-2025-07
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma, Ependymoma, Vestibular Schwannoma
- Keywords
- NF2-SWN, Selumetinib
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- AstraZeneca
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.
Detailed description
NF2-related schwannomatosis (NF2-SWN) is a rare, autosomal dominant tumor predisposition syndrome characterized by bilateral vestibular schwannomas and multifocal schwannomas arising from cranial, spinal, and peripheral nerves, frequently leading to progressive hearing loss, neurological deficits, and substantial morbidity. This study will serve as a Substudy component of the "Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)" initiative, conducting a single-center, single-arm Phase II clinical trial aimed at evaluating the efficacy and safety of selumetinib in treating NF2-SWN-associated tumors. The study will enroll 20 patients diagnosed with NF2-related schwannomatosis (NF2-SWN) who have at least one measurable and progressive vestibular schwannoma and are aged ≥3 years. The primary endpoints include: ① Imaging response rate for NF2-SWN-associated vestibular schwannomas, assessed by a reduction of ≥20% in volume according to the REiNs criteria; ② Hearing response rate, defined as an improvement in speech recognition rate exceeding the 95% threshold difference. Secondary endpoints involve quality-of-life assessment: all patients will undergo evaluation using the NF2-SWN-specific Quality of Life Scale (NFTI-QOL), with additional pain scoring using the Numerical Rating Scale-11 (NRS-11) for patients with NF2-SWN-related intraspinal space-occupying lesions. The exploratory endpoints included: ① Imaging response rates for other NF2-SWN-related tumors excluding NF2-SWN-associated vestibular schwannomas: for meningiomas (non-vestibular schwannomas), objective imaging response defined as a volume reduction ≥20% per the REiNs criteria; for ependymomas, objective imaging response defined as a maximum diameter reduction ≥30% per the RECIST 1.1 criteria; total tumor burden; and the TSPO-PET/MRI-defined immune phenotype (immune-enriched vs. immune-depleted) and its association with treatment response in NF2-SWN-associated vestibular schwannomas. This study will provide further clinical evidence for targeted therapy of NF2-SWN.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Selumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment.
| Arm | Type | Receives |
|---|---|---|
| Selumetinib | Experimental | Drug: SelumetinibSelumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment. |
Who may qualify
- Ages
- 3 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (56 listed)
- Patients must have a pathogenic variant in the NF2 gene (either in the germline or in two NF2-related tumors)OR a confirmed diagnosis of NF2 by fulfilling National Institute of Health (NIH)criteria or Manchester criteria:
- The genetic test report should be issued by companies or hospitals with corresponding qualifications.
- Subjects must have ≥1 measurable target vestibular schwannoma meeting all of the following conditions:
- The target tumor must be considered not amenable to surgery due to:
- Male or female subjects aged ≥3 years at the time of informed consent.
Key exclusion criteria (24 listed)
- Concurrent involvement in study conduct:the subject is an employee of the Sponsor, Investigator, or study site who is directly involved in the planning, conduct, or management of this clinical study.
- Participation in another interventional clinical trial with an investigational medicinal product, or receipt of an investigational agent within 28 days (or 5 half-lives if known and longer)prior to first dose.
- Prior anti-cancer systemic therapies or prior radiotherapy that, in the investigator's judgment, would confound safety or efficacy assessment, unless completed ≥28 days prior to first dose (longer washout required for agents with prolonged biologic effect as specified in protocol appendix). Subjects who received prior local therapy (surgery or localized radiotherapy)are eligible if recovery is complete and target lesion remains measurable.
- Evidence or high suspicion of malignant peripheral nerve sheath tumor (MPNST)or other active malignancy requiring systemic therapy (past malignancy is allowed only if disease-free for ≥2 years, except for adequately treated basal cell carcinoma or in situ carcinoma).
- Significant cardiac disease or ECG abnormalities:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SelumetinibAlso: KOSELUGOSelumetinib will be administered at a dose of 25 mg/m²orally twice daily (BID),with a maximum single dose of 50 mg per administration.Doses will be calculated based on body surface area (BSA)and rounded to the nearest 5 mg increment. | Drug | Selumetinib |
Primary outcome
Objective Response Rate (ORR)in NF2-related vestibular schwannoma assessed according to the REiNS criteria
Time frame: 12 months
Partial response is defined as the sum volume of VS decrease ≥20% compared to baseline, confirmed by a consecutive scan after 1 to 3 treatment cycles after the first response. Complete response is defined as disappearance of VS, confirmed by a consecutive scan after 1 to 3 treatment cycles after the first response;
Hearing Response Rate Based on Word Recognition Score (WRS) in Target Vestibular Schwannoma
Time frame: 12 months
Percentage of participants with WRS improvement exceeding the 95% critical difference from baseline in the ear associated with the target vestibular schwannoma.
Pure Tone Average (PTA) Response Rate in Target Vestibular Schwannoma
Time frame: 12 months
Percentage of participants with a PTA decrease of at least 10 dB from baseline in the ear associated with the target vestibular schwannoma.
1 secondary outcome
Assess safety and tolerability especially for selumetinib
Time frame: From the first dose of study drug (Day 0) through 30 ± 3 days after the last dose administration.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared. This decision is based on: (1) the rare disease nature of NF2-SWN and small sample size (n=20), which increases re-identification risk even after de-identification; (2) protection of participant privacy and confidentiality as required by Chinese ethics regulations and the informed consent process; and (3) proprietary considerations of the study sponsor regarding investigational product data.
Related trials for Neurofibromatosis Type 2
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Active, not recruitingPhase 2
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
RecruitingPhase 1
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NF1 Mutation, Neurofibroma Plexiform
RecruitingPhase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Neurofibromatosis Type 2, Vestibular Schwannoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Selumetinib in people with Neurofibromatosis Type 2 and NF2, run by Beijing Tiantan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 56 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pinan Liu, PhD (010-59976611, pinanliu@ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response Rate (ORR)in NF2-related vestibular schwannoma assessed according to the REiNS criteria (time frame: 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.